Strategic Business Reporting - Ethics and Professional Principles

SECTION A - QUESTION 2 GenoCure is a biotechnology company developing advanced gene therapies. The company is preparing its financial statements for the year ended 31 October 20X5. GenoCure is currently seeking a lucrative Initial Public Offering (IPO) in early 20X6. You are the newly appointed Chief Financial Officer (CFO), a qualified accountant. The Chief Executive Officer (CEO), who is also the majority shareholder, has presented you with two issues: Issue 1: Research and Development (R&D) During the year, GenoCure spent $12 million on a new gene therapy project, 'Helix-X'. $4 million was spent on early-stage laboratory research. The remaining $8 million was spent on Phase 1 clinical trials. While the Phase 1 trials showed promising safety profiles, efficacy has not yet been proven, and regulatory approval is at least three years away. The CEO has instructed you to capitalize the entire $12 million as an intangible asset, stating, "Our investors need to see a strong balance sheet for the IPO. If we expense this, our profit margins will look terrible, and the IPO valuation will collapse." Issue 2: Related Party Transaction GenoCure outsourced its data analysis for the clinical trials to 'DataGen', a company wholly owned by the CEO's brother. GenoCure paid DataGen $3 million for these services. Independent market analysis indicates that the arm's length commercial rate for identical services is $1.5 million. The CEO has told you not to disclose this transaction in the financial statements, arguing, "It's a standard service contract, and disclosing it will just invite unnecessary scrutiny from potential IPO investors." Required: (a) Discuss the correct accounting treatment for the R&D expenditure under IAS 38 Intangible Assets, and the transaction with DataGen under IAS 24 Related Party Disclosures. (10 marks) (b) Discuss the ethical and professional issues you face as the CFO of GenoCure, and recommend appropriate actions you should take to resolve them. (10 marks)